Sorted By:

Relevance


Costs and Consequences of Not Treating High Cholesterol

PhRMA  |  Blog Post

Stay tuned for the next post in the “Costs and Consequences” series and be sure to share your thoughts in the comments section below.
http://catalyst.phrma.org/costs-and-consequences-of-not-treating-high-cholesterol

Patience, Hope and Survival: Progress on the Cancer Front

PhRMA  |  Blog Post

The science is difficult and the business and policy environments increasingly put pressure on innovation.
http://catalyst.phrma.org/patience-hope-and-survival-progress-on-the-cancer-front

Ask About Adherence: Q&A with Dr. Helaine Resnick on diabetes care

PhRMA  |  Blog Post

 Future research could focus on improved understanding of providers’ perceptions about their patients, and whether improved communication reduces variance from practice guidelines when treatment intensification is a goal that is shared by both the patient and his or her physician.
http://catalyst.phrma.org/ask-about-adherence-q-and-a-with-dr.-helaine-resnick-on-diabetes-care

4 Ways To Better Engage And Empower Patients

Access Better Coverage  |  From Our Network

State and federal regulators should prohibit insurers from structuring plans in this fashion, so patients are not discouraged from enrolling in a plan because of a health condition.
http://www.accessbettercoverage.org/articles/4-ways-to-better-engage-and-empower-patients

Power of Medicines: Saving Lives and Building the Future

PhRMA  |  Video

These advances improve the lives of patients and can often help avoid hospital visits, surgeries and long-term care.
https://www.phrma.org/video/the-power-of-medicines-saving-lives-and-building-for-the-future

Collaboration Is Key in Researching and Developing New Medicines

Chartpack  |  From Our Network

The Accelerating Medicines Partnership, Biomarkers Consortium and Lung Cancer Master Protocol are a few examples of current collaborative efforts.
http://chartpack.phrma.org/biophrma-chartpack/research-and-development/collaboration-is-key-in-researching-and-developing-new-medicines

Partnerships and Collaborations are Transforming the Research and Development of Personalized Medicines

Chartpack  |  From Our Network

Collaborations like the Accelerating Medicines Partnership, the Biomarkers Consortium and the Lung Cancer Master Protocol are crucial to maintaining robust biopharmaceutical innovation in the United States. 
http://chartpack.phrma.org/personal-medicines-in-development-chartpack/an-evolving-pipeline/partnerships-and-collaborations-are-transforming-the-research-and-development-of-personalized-medicines

Policy Solutions: Engaging and Empowering Consumers

PhRMA  |  Report

And yet, consumers too often are frustrated by hurdles that make it hard to access information about their insurance benefits and out-of-pocket health care costs.
https://www.phrma.org/report/engaging-and-empowering-consumers

Earlier and More Frequent Patent Challenges by Generic Companies

Chartpack  |  From Our Network

As early as 4 years after brand launch, a generic company may file with FDA a Paragraph IV certification to “challenge” patents associated with the brand name medicine, often allowing generic market entry before the patent expiration date....
http://chartpack.phrma.org/biophrma-chartpack/research-and-development/earlier-and-more-frequent-patent-challenges-by-generic-companies

Recommended Medicines Can Save Lives and Dramatically Improve Health

Chartpack  |  From Our Network

Recommended use of antihypertensive medicines reduce the number of hospitalizations and deaths.
http://chartpack.phrma.org/biophrma-chartpack/outcomes-and-savings/recommended-medicines-can-save-lives-and-dramatically-improve-health

Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones

PhRMA  |  Report

These medicines promise to improve cure rates further, reduce side effects and duration of treatment, and expand treatment options.
https://www.phrma.org/report/twenty-five-years-of-progress-against-hepatitis-c-setbacks-and-stepping-stones

New Research: Access and quality implications of CMS proposed Part B model

PhRMA  |  Blog Post

Discern Health identified several gaps and risks in the Part B Drug Payment Model design, including: The mandatory participation requirement, which could disrupt care delivery that is already complex for many patients; A lack of necessary quality measures available to capture patient-reported quality outcomes; A failure to evaluate the impact on outcomes, such as survival and quality of life; and The broad scope of the model, which will necessitate immense resources for adequate monitoring and evaluation.
http://catalyst.phrma.org/new-research-access-and-quality-implications-of-cms-proposed-part-b-model

Preventive Care And High Deductibles Work At Cross Purposes, Covered Cal Chief Says

Access Better Coverage  |  From Our Network

“Employers and health plans in the public sector have benefit designs that directly conflict with the goal of the ACA.
http://www.accessbettercoverage.org/social-news/preventive-care-and-high-deductibles-work-at-cross-purposes-covered-cal-chief-says

Biologics & Biosimilars

PhRMA  |  From PhRMA

To facilitate effective pharmacogilivance, support appropriate patient care, and facilitate reimbursement, CMS should provide for a separate HCPCS billing codes and reimbursement for each biosimilar biologic product.
https://www.phrma.org/advocacy/research-development/biologics-biosimilars

PhRMA Reports 836 Medicines and Vaccines in Development to Treat Cancer

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.
https://www.phrma.org/press-release/phrma-reports-836-medicines-and-vaccines-in-development-to-treat-cancer

Addressing Health Care Challenges Through Unique Ideas and Perspectives

PhRMA  |  Blog Post

Our team is eager to hear your thoughts and feedback as we pull this together.
http://catalyst.phrma.org/addressing-health-care-challenges-through-unique-ideas-and-perspectives

The Story of Olof Larsson, Eli Lilly and Company

PhRMA  |  Video

This initiative provides an opportunity for scientists working in drug discovery and development at America's biopharmaceutical companies to showcase their heroic and exciting work to younger generations while at the same time, bring to light what they do outside of work for fun.
https://www.phrma.org/video/the-story-of-olof-larsson-eli-lilly-and-company

Careers

PhRMA  |  From PhRMA

PhRMA’s current employment opportunities are listed below, and this listing is updated regularly.
https://www.phrma.org/about/careers

PhRMA Honored for Supporting Employees Serving in Military Reserve and Federal Disaster Support Systems

PhRMA  |  Press Release

Antony is PhRMA’s Chief Medical Officer and Dr.
https://www.phrma.org/press-release/phrma-honored-for-supporting-employees-serving-in-military-reserve-and-federal-disaster-support-systems

PhRMA Webcast to Examine Progress and Promise of Alzheimer’s Research

PhRMA  |  Blog Post

Egge, chief public policy officer, Alzheimer’s Association Sue Peschin, MHS, president and chief executive officer, Alliance for Aging Research George A.
http://catalyst.phrma.org/phrma-webcast-to-examine-progress-and-promise-of-alzheimers-research

Matt and Jamie share their stories in new “From Hope to Cures” ads

PhRMA  |  Blog Post

In addition to sharing real stories from patients and researchers, the campaign highlights data and information on fighting diseases, clinical trials and the economic contributions of the biopharmaceutical industry.
http://catalyst.phrma.org/matt-and-jamie-share-their-stories-in-new-from-hope-to-cures-ads

340B Spotlight: A look at 340B eligibility and charity care

PhRMA  |  Blog Post

And tune in today to AIR340B’s Summit using #340BSummit.
http://catalyst.phrma.org/340b-spotlight-a-look-at-340b-eligibility-and-charity-care

Researchers and Patient Advocates Honored with PhRMA Award

PhRMA  |  Press Release

The nominations were reviewed and discussed at length and chosen by a group of individuals with extensive knowledge and experience in the science and patient advocacy fields. 
https://www.phrma.org/press-release/researchers-and-patient-advocates-honored-with-phrma-award

PhRMA Member Companies Invested $49.5 Billion In Research and Development in 2011

PhRMA  |  Press Release

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives.
https://www.phrma.org/press-release/phrma-member-companies-invested-49-5-billion-in-research-and-development-in-2011

The War on Alzheimer’s: Progress and Challenges of Biopharmaceutical Research

PhRMA  |  Blog Post

The biopharmaceutical industry is committed to continuing research efforts to enhance treatments, find a cure and provide hope to millions of patients and their families worldwide.
http://catalyst.phrma.org/the-war-on-alzheimers-progress-and-challenges-of-biopharmaceutical-research

You have reviewed the first 200 results out of 2501. Each page contains 25 results. You're on page 8.

prev 7 8 9 10 11 12 next